Q3 2022 Results

Company overview Financial review 2022 priorities Appendix References 3 INNOVATION APPLY-PNH demonstrated clinically meaningful superiority vs. anti-C5 Anti-C5 antibody Up to 8 weeks LNP023 200mg BID (n=62) Continue with LNP023 200mg BID Anti-C5 antibody (n= 35) Switch to LNP023 200mg BID 24 weeks D-60 D1 Screening period Randomized treatment period 24 weeks D168 D336 EoS Treatment extension period Population (n = 97) Adult PNH patients with residual anemia (Hb <10g/dL) on a stable regimen of anti-C5 therapy 6 months prior to randomization Primary endpoints Superiority for proportion of patients achieving increase in Hb ≥2g/dL from baseline in the absence of RBC transfusion ☑ Superiority for proportion of patients achieving Hb ≥12g/dL in the absence of RBC transfusion Oral monotherapy iptacopan demonstrates clinically meaningful superiority over anti-C5 treatment in Ph3 Met 2 primary endpoints for superiority in PNH patients with residual anemia despite prior anti-C5 treatment PNH - paroxysmal nocturnal hemoglobinuria Hb - Hemoglobin RBC Red Blood Cell BID twice a day EOS end of study 17 Investor Relations | Q3 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation